Wellesley, MA (PRWEB) May 16, 2013
Infectious diseases have haunted humans throughout history, influencing societies socially and economically. Because of the number of different infectious diseases, several types of transmission routes are possible. Some diseases are spread through contaminated food, water, fecal material, body fluids, or animal products. Others are transmitted through the air. Still others are transmitted by parasites such as flukes, mosquitoes, and flies. Transmission routes are becoming increasingly important, as large numbers of people travel globally, giving them the ability to rapidly transmit a disease from one area to another.
Infectious diseases rank second as the cause of death globally. They are prevalent throughout the world but are especially problematic in middle-income to low-income countries. According to the World Health Organizations (WHO), infectious diseases cause 16.2% of global deaths each year, with children as the most vulnerable group.
The global market for infectious disease diagnostic, vaccine, and treatment products is expected to grow at a compound annual growth rate (CAGR) of 7.8%. Much of the growth is being driven by emerging markets in the BRIC (i.e., Brazil, Russia, India, and China) countries. Hepatitis products will continue to expand in areas such as India and China where infection rates are especially high.
The vaccine market for infectious diseases was estimated at nearly $19 billion in 2012, with a CAGR of 6.9%. Growth rates are led by rotavirus vaccines at a CAGR of 21.5%, with most of the projected growth outside developed countries that already have vaccination programs well under way. As calculated in this report, vaccines constitute approximately 27% of the infectious disease product market.
Even though more than 17% of the market consists of antibacterials, this market is also the most vulnerable, given the increasing rate of antibiotic-resistant organisms and the lack of new types of antibacterials in pharmaceutical company pipelines. This market shows the slowest CAGR at slightly more than 6%, but holds the possibility of more rapid growth with the introduction of newer antibiotics that can help combat antibiotic-resistant organisms.
Pharmaceuticals make up the fastest-growing segment of the market at a CAGR of 8.3%, leading to a projected market of nearly $66 billion by 2017. The major driver of this segment is hepatitis drugs, primarily those for hepatitis B and, increasingly, those for hepatitis C.
In relation to this report, the infectious disease diagnostic, vaccine and pharmaceutical products tracked include human immunodefiency virus (HIV); hepatitis A, B, C; respiratory synctial virus (RSV); rotavirus/diarrhea; viral and bacterial pneumonia; tuberculosis (TB); sexually transmitted diseases including candidiasis, chancroid, chlamydia, gonorrhea, pediculosis pubis, syphilis, human papillomavirus (HPV), herpes simplex virus (HSV); malaria; and childhood diseases including measles, mumps, rubella, diphtheria, tetanus, pertussis, polio and Haemophilus influenzae.
Global Markets for Infectious Disease Treatments (PHM061B) provides the reader with a detailed analysis of the global infectious disease market, with emphasis on seven major infectious diseases (i.e., human immunodeficiency virus/acquired immunodeficiency virus [HIV/AIDS]; hepatitis A, B, C; malaria, rotavirus/diarrhea; measles; pneumonia; and tuberculosis [TB]).
The report also discusses technological developments, future trends, and emerging opportunities. The major objectives of this study are:
•Assessing the current state of infectious diseases on a global basis
•Identifying the driving factors for demand of new diagnostic and pharmaceutical products
•Estimating current and future market sizes for diagnostic and pharmaceutical infectious disease products
•Estimating the current global supply-and-demand scenario, by disease type and geographical regions
•Identifying factors that influence the industry and proposing market opportunities.